Clinical Trial

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators hypothesize that zanzalintinib maintenance therapy after initial cytotoxic chemotherapy can prolong the progression-free survival (PFS) in patients with high-grade NENs.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-10; most recent amendment 2025-12-10.
Status change: Not Yet Recruiting → Recruiting 2025-12-10
Trial Details
NCT Number NCT06926634
Lead Sponsor Washington University School of Medicine
Collaborators: Exelixis
Conditions High Grade Neuroendocrine Neoplasms
Enrollment 32 participants
Start Date 2025-12-09
Primary Completion 2034-12-31 (estimated)
Study Completion 2034-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-17